Approval · Notice of Compliance 9974 · 2008

3TC: Notice of Compliance 9974

Issued December 24, 2008

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 9974
Date: December 24, 2008
Company: Glaxosmithkline Shire Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Antiretroviral agent

Products in this notice

Brand	DIN	Status today
3TC	02192683	Marketed
3TC	02247825	Marketed
3TC	02192691	Marketed

Medicinal ingredients

LAMIVUDINE 150 MG per TAB
LAMIVUDINE 300 MG per TAB
LAMIVUDINE 10 MG per ML